241 related articles for article (PubMed ID: 30198057)
1. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M
Invest New Drugs; 2018 Dec; 36(6):1072-1084. PubMed ID: 30198057
[TBL] [Abstract][Full Text] [Related]
2. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B
J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Streubel G; Schrepfer S; Kallus H; Parnitzke U; Wulff T; Hermann F; Borgmann M; Hamm S
Sci Rep; 2021 May; 11(1):9587. PubMed ID: 33953226
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of resminostat in Japanese patients with advanced solid tumors.
Kitazono S; Fujiwara Y; Nakamichi S; Mizugaki H; Nokihara H; Yamamoto N; Yamada Y; Inukai E; Nakamura O; Tamura T
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1155-61. PubMed ID: 25847480
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Lim HY; Heo J; Choi HJ; Lin CY; Yoon JH; Hsu C; Rau KM; Poon RT; Yeo W; Park JW; Tay MH; Hsieh WS; Kappeler C; Rajagopalan P; Krissel H; Jeffers M; Yen CJ; Tak WY
Clin Cancer Res; 2014 Dec; 20(23):5976-85. PubMed ID: 25294897
[TBL] [Abstract][Full Text] [Related]
8. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Ikeda M; Ohno I; Ueno H; Mitsunaga S; Hashimoto Y; Okusaka T; Kondo S; Sasaki M; Sakamoto Y; Takahashi H; Hara R; Kobayashi S; Nakamura O; Morizane C
Invest New Drugs; 2019 Feb; 37(1):109-117. PubMed ID: 29995287
[TBL] [Abstract][Full Text] [Related]
11. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Brunetto AT; Ang JE; Lal R; Olmos D; Molife LR; Kristeleit R; Parker A; Casamayor I; Olaleye M; Mais A; Hauns B; Strobel V; Hentsch B; de Bono JS
Clin Cancer Res; 2013 Oct; 19(19):5494-504. PubMed ID: 24065624
[TBL] [Abstract][Full Text] [Related]
12. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells.
Fu M; Shi W; Li Z; Liu H
Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
16. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
17. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
[TBL] [Abstract][Full Text] [Related]
19. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S; Bi F; Gu S; Bai Y; Chen Z; Wang Z; Ying J; Lu Y; Meng Z; Pan H; Yang P; Zhang H; Chen X; Xu A; Cui C; Zhu B; Wu J; Xin X; Wang J; Shan J; Chen J; Zheng Z; Xu L; Wen X; You Z; Ren Z; Liu X; Qiu M; Wu L; Chen F
J Clin Oncol; 2021 Sep; 39(27):3002-3011. PubMed ID: 34185551
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
Lachenmayer A; Toffanin S; Cabellos L; Alsinet C; Hoshida Y; Villanueva A; Minguez B; Tsai HW; Ward SC; Thung S; Friedman SL; Llovet JM
J Hepatol; 2012 Jun; 56(6):1343-50. PubMed ID: 22322234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
